GlassScriptPhysician profile
Jodee Elizabeth Ahrens
NPI 1770584088
$3,266.93
in general payments reported to CMS, 2019-2025
30 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $80.01 · 2021: $92.14 · 2022: $483 · 2023: $526 · 2024: $680 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.48 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $723.74 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $365.12 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $319.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $242.85 | 2019-2025 | |
| Abbvie INC. | $232.57 | 2021-2024 | Vraylar |
| Merck Sharp & Dohme LLC | $163.96 | 2019 | |
| Exact Sciences Corporation | $130.92 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $126.84 | 2019-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $100.23 | 2022 | |
| Abbott Laboratories | $89.58 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.95 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $87.71 | 2019-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $87.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.87 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $59.17 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $52.66 | 2019-2024 | Eohilia |
| Kowa Pharmaceuticals America, INC. | $41.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.73 | 2019-2020 | |
| Corcept Therapeutics | $34.14 | 2019 | |
| Eisai INC. | $32.64 | 2019 | |
| Allergan, INC. | $27.01 | 2019 | |
| Scilex Pharmaceuticals INC. | $23.73 | 2019 | |
| Medtronic, INC. | $22.37 | 2024 | Closurerfg |
| Otsuka America Pharmaceutical, INC. | $18.44 | 2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $15.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.87 | 2023 | Camzyos |
| Horizon Therapeutics Plc | $15.00 | 2021 | |
| Hikma Pharmaceuticals USA | $14.38 | 2019 | |
| Circassia INC. | $14.32 | 2019 | |
| Amarin Pharma, INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodee Ahrens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.